Ascenta Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to discovering and developing new medicines to stop cancer. Our core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. We have a compound in Phase IIb cancer clinical trials that inhibits the Bcl-2 family of proteins (Bcl-2, Bcl-xL, Bcl-w, and Mcl-1) and a pipeline that targets HDM2 (inhibitor of the p53 tumor suppressor protein) and XIAP (inhibitors of apoptosis proteins).
To explore available investment possibilities and receive a nondisclosure agreement, please contact Business Development at email@example.com.
Ascenta's financing partners come from the top tier of biotech venture companies, who are among the most established and well funded in their fields. Ascenta has had three rounds of financing to date.